WallStSmart

Edwards Lifesciences Corp (EW)vsTivic Health Systems Inc (TIVC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Edwards Lifesciences Corp generates 1258738% more annual revenue ($6.07B vs $482,000). EW leads profitability with a 17.7% profit margin vs 0.0%. EW earns a higher WallStSmart Score of 55/100 (C).

EW

Buy

55

out of 100

Grade: C

Growth: 4.0Profit: 7.0Value: 7.3Quality: 4.8
Piotroski: 2/9

TIVC

Avoid

31

out of 100

Grade: F

Growth: 4.7Profit: 2.5Value: 5.0Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

EWSignificantly Overvalued (-544.4%)

Margin of Safety

-544.4%

Fair Value

$12.31

Current Price

$82.67

$70.36 premium

UndervaluedFair: $12.31Overvalued

Intrinsic value data unavailable for TIVC.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EW1 strengths · Avg: 8.0/10
Operating MarginProfitability
23.7%8/10

Strong operational efficiency at 23.7%

TIVC2 strengths · Avg: 9.0/10
Price/BookValuation
0.3x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
15.9%8/10

15.9% revenue growth

Areas to Watch

EW4 concerns · Avg: 2.8/10
PEG RatioValuation
2.144/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

P/E RatioValuation
45.7x2/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-76.6%2/10

Earnings declined 76.6%

TIVC4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$2.58M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-1.8%2/10

ROE of -1.8% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : EW

The strongest argument for EW centers on Operating Margin. Profitability is solid with margins at 17.7% and operating margin at 23.7%. Revenue growth of 13.3% demonstrates continued momentum.

Bull Case : TIVC

The strongest argument for TIVC centers on Price/Book, Revenue Growth. Revenue growth of 15.9% demonstrates continued momentum.

Bear Case : EW

The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 45.7x leaves little room for execution misses.

Bear Case : TIVC

The primary concerns for TIVC are EPS Growth, Market Cap, Profit Margin.

Key Dynamics to Monitor

EW profiles as a mature stock while TIVC is a growth play — different risk/reward profiles.

TIVC carries more volatility with a beta of 2.01 — expect wider price swings.

TIVC is growing revenue faster at 15.9% — sustainability is the question.

EW generates stronger free cash flow (354M), providing more financial flexibility.

Bottom Line

EW scores higher overall (55/100 vs 31/100), backed by strong 17.7% margins and 13.3% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Edwards Lifesciences Corp

HEALTHCARE · MEDICAL DEVICES · USA

Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.

Visit Website →

Tivic Health Systems Inc

HEALTHCARE · MEDICAL DEVICES · USA

Tivic Health Systems Inc (TIVC) is a pioneering medical technology firm focused on developing non-invasive bioelectronic therapies aimed at addressing chronic conditions, particularly allergic rhinitis. Leveraging its proprietary platform and extensive clinical expertise, Tivic Health is committed to delivering innovative solutions that not only meet critical patient needs but also optimize healthcare delivery. Positioned at the vanguard of the burgeoning bioelectronic medicine landscape, the company is set to seize emerging market opportunities, significantly improving patient outcomes and establishing new benchmarks in chronic condition management.

Want to dig deeper into these stocks?